Publicação
Efeitos metabólicos associados à terapêutica anti-retroviral na infecção por VIH-1 : a experiência de utilização do atazanavir na prática clínica
| dc.contributor.advisor | Valadas, Emília, 1962- | pt |
| dc.contributor.author | Santos, Andreia Sofia M., 1980- | pt |
| dc.date.accessioned | 2010-07-22T08:48:11Z | |
| dc.date.available | 2010-07-22T08:48:11Z | |
| dc.date.issued | 2009 | pt |
| dc.description | Tese de mestrado, Doenças Infecciosas Emergentes, Faculdade de Medicina, Universidade de Lisboa, 2009 | pt |
| dc.description.abstract | The lipid profile of individuals infected with HIV-1 is characterized with high levels of total cholesterol, LDL cholesterol and triglycerides e low levels of HDL cholesterol. The regimens based in atazanavir (ATV) revealed improved metabolic and lipid profile in comparison with other protease inhibitors, with identical viral suppression. The objectives of this study were to analyse the efficacy and safety of boosted ATV as part of combination antiretroviral therapy in HIV-1 infected patients. Study sample consisted of patients medicated with ATV/RTV at least for 6 months. Patients were recruited at the Infectious Diseases Department of Santa Maria Hospital in Lisbon. Clinical files were analyzed, including demographic, clinical, and laboratory data, as well as history of present and past therapy. Data from 190 patients was collected and analyzed in five different moments: before treatment with ATV/RTV, and at month 6, 12, 18, and 24. Safety of ATV/RTV was evaluated in terms of lipid and metabolic profile improvements, whereas the efficacy was established through HIV-1 viral load, and levels of T CD4+ cells. The use of ATV/RTV therapy was associated with no alteration in metabolic and lipid profile, meaning that this therapy does not increase the levels of total cholesterol, LDL, triglycerides and glycemia. The improved lipid and metabolic profile can reduce the cardiovascular risk and the metabolic complications of the patients doing this type of therapy. The efficacy was accomplished with a statistical significant reduction in viral load and a significant increase in CD4+ T cell counts. | pt |
| dc.description.abstract | Resumo alargado em português | pt |
| dc.format | application/pdf | pt |
| dc.identifier.uri | http://catalogo.ul.pt/F/?func=item-global&doc_library=ULB01&type=03&doc_number=000564277 | pt |
| dc.identifier.uri | http://hdl.handle.net/10451/1048 | |
| dc.language.iso | por | pt |
| dc.subject | HIV-1 | pt |
| dc.subject | Terapêutica anti-retroviral | pt |
| dc.subject | Complicações metabólicas | pt |
| dc.subject | Dislipidémia | pt |
| dc.subject | Lipodistrofia | pt |
| dc.subject | Atazanavir | pt |
| dc.subject | Inibidores de proteases | pt |
| dc.subject | Teses de mestrado - 2009 | pt |
| dc.title | Efeitos metabólicos associados à terapêutica anti-retroviral na infecção por VIH-1 : a experiência de utilização do atazanavir na prática clínica | pt |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | restrictedAccess | pt |
| rcaap.type | masterThesis | pt |